ENDO 2026 attendees who catch the session, “Weight Loss: Friend or Foe for Bone & Muscle?” will be in for a treat as three experts weigh in on the impact of various weight loss therapies on muscle and bone. Pharmacological, surgical, and even lifestyle impacts will be discussed and debated in this Sunday morning symposium.
On Sunday, June 14, ENDO 2026 will feature “Weight Loss: Friend or Foe for Bone & Muscle?,” a session that complements the menopause session happening a day earlier (and also featured in this issue). The Sunday session will characterize the effects of different methods of weight loss on musculoskeletal health in people living with obesity and discuss current management approaches including lifestyle and pharmacologic treatments.
Of the three presenters, two will discuss the role of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in this dynamic, and one will cover how bariatric surgery fits in.
Endocrine News published a clinical update in Research Highlights on 21 May 2026.
The item focuses on Breaking Point: Weight Loss Therapies and the Musculoskeletal Stakes.
Review the original article for the full source wording and details.